Table 2. Results of economic evaluation analysis on Argus II prosthesis.

Author, year, location	Study design and perspective	Population	Interventions/ comparators	Health outcomes	Costs	Cost-effectiveness
Vaidya et al, 2014[4], United Kingdom	Cost-effectiveness analysis (utility measured as QALYs); Multi-state transition Markov model; Health care payer's perspective	n=1000 patients with retinitis pigmentosa; Mean age 46y and older	Argus II vs usual care	Expected QALYs: Base case analysis: Argus II: 7.34 usual care: 4.44.	Base case analysis: Argus II: €243 549; usual care: €201 094	€14 603/QALY
Health Quality Ontario[19], 2016 Canada	Cost-utility analysis (utility measured as QALYs); Markov cohort model; Perspective of the Ontario Ministry of Health and Long-Term Care.	n=1000 patients with retinitis pigmentosa; Men and/or women aged 50y and older	Argus II vs usual care	Utility: retinitis pigmentosa, no light perception=0.26; no grating visual acuity, light perception=0.35, grating visual acuity=0.52; average total effect: Argus II=3.21; standard care=2.08	Average total cost Argus II=$361 034; Standard care=$126 428	$207 616/QALY

QALY: Quality-adjusted life year.